97030 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Receptors; Cell surface antigens; Cell surface determinants; Immunoglobulin superfamily CD2
USE OF INTERLEUKIN-7 AND CHIMERIC ANTIGEN RECEPTOR (CAR)-BEARING IMMUNE EFFECTOR CELLS FOR TREATING TUMOR
#2SARS-CoV-2 Vaccine Constructs
#3METHODS FOR DIAGNOSING OR TREATING HEALTH CONDITIONS OR OPTIMIZING THERAPEUTIC EFFICACY OF CAR-T CELLS THERAPIES
#4CD79A CHIMERIC ANTIGEN RECEPTORS
#5IMMUNOMODULATORY FUSION PROTEINS AND USES THEREOF
#6CD79A CHIMERIC ANTIGEN RECEPTORS
#7BINDING DOMAIN
#8Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid Tumors
#9COMPOSITIONS AND METHODS OF TREATING DISEASE WITH CHIMERIC ANTIGEN RECEPTORS TO B CELL MATURATION ANTIGEN (BCMA)
#10HYBRID RECEPTORS WITH MULTIPLE TRANSCRIPTIONAL REGULATORS
#11Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemias
#12ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF
#13ENHANCED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTOR CELL ENGINEERING AND USE THEREOF
#14IMMUNE CELLS EXPRESSING AN ANTIGEN BINDING RECEPTOR AND A CHIMERIC COSTIMULATORY RECEPTOR
#15CHIMERIC RECEPTOR CONSTRUCTS FOR NK CELLS
#16ANTI-ANGIOGENIC AGENT AND METHODS OF USING SUCH AGENT
#17CHIMERIC ACTIVATION RECEPTORS
#18CHIMERIC SWITCH RECEPTORS FOR THE CONVERSION OF IMMUNESUPPRESSIVE SIGNALS TO COSTIMULATORY SIGNALS
#19Use of CD2/5/7 Knock-Out Anti-CD2/5/7 Chimeric Antigen Receptor T cells Against T Cell Lymphomas and Leukemias
#20CHIMERIC ANTIGEN RECEPTOR T CELLS FOR TREATING AUTOIMMUNITY
#21T CELLS AND CHIMERIC STIMULATING RECEPTORS AND USES THEREOF
#22VACCINES AGAINST AFRICAN SWINE FEVER VIRUS, AND METHODS OF USING SAME
#23USE OF THE CD2 SIGNALING DOMAIN IN SECOND-GENERATION CHIMERIC ANTIGEN RECEPTORS
#24CHIMERIC ANTIGEN RECEPTORS WITH CD2 ACTIVATION
#25GLYPICAN-2-BINDING MOIETIES, CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
#26COMPOSITIONS AND METHODS FOR T CELL ENGINEERING
#27BLOCKING CHIMERIC ANTIGEN RECEPTORS FOR PREVENTION OF UNDESIRED ACTIVATION OF EFFECTOR AND REGULATORY IMMUNE CELLS
#28ALLOGENEIC CELL COMPOSITIONS AND METHODS OF USE
#29ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
#30ALLOGENEIC CELL COMPOSITIONS AND METHODS OF USE
#31CHIMERIC CO-STIMULATORY PROTEINS COMPRISING MUTANT INTRACELLULAR DOMAINS WITH INCREASED EXPRESSION
#32ENHANCEMENT OF POLYPEPTIDES AND CHIMERIC ANTIGEN RECEPTORS VIA HINGE DOMAINS
#33Use of CD2/5/7 knock-out anti-CD2/5/7 chimeric antigen receptor T cells against T cell lymphomas and leukemias
#34XBP1, CD138, AND CS1 PEPTIDES
#35Immunomodulatory fusion proteins and uses thereof
#36ANTI-CD33 AND NKG2D LIGAND CHIMERAS FOR TREATMENT OF MYELOID MALIGNANCIES
#37Use of the CD2 signaling domain in second-generation chimeric antigen receptors
#38Tn-MUC1 Chimeric Antigen Receptor (CAR) T Cell Therapy
#39COMPOSITIONS AND METHODS FOR T CELL ENGINEERING
#40USE OF INTERLEUKIN-7 AND CHIMERIC ANTIGEN RECEPTOR (CAR)-BEARING IMMUNE EFFECTOR CELLS FOR TREATING TUMOR
#41CHIMERIC RECEPTORS TO STEAP1 AND METHODS OF USE THEREOF
#42CD79A chimeric antigen receptors
#43Blockade of CD2 surface expression and expression of chimeric antigen receptors for immunotherapy of T-cell malignancies
#44T cell disease treatment targeting TAG-72
#45Chimeric Antigen Receptor T Regulatory Cells for the Treatment of Atherosclerosis
#46Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid Tumors
#47Tn-MUC1 chimeric antigen receptor (CAR) T cell therapy
#48IN VIVO PRIMING OF NATURAL KILLER CELLS
#49THERAPEUTIC REGIMENS FOR CHIMERIC ANTIGEN RECEPTOR THERAPIES
#50THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
#51Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor
#52Use of the CD2 signaling domain in second-generation chimeric antigen receptors
#53Anti-CD7 chimeric antigen receptor and method of use thereof
#54Recombinant vectors comprising 2A peptide
#55Use of chimeric antigen receptor modified cells to treat cancer
#56IMMUNOMODULATORY FUSION PROTEINS AND USES THEREOF
#57Use of the CD2 signaling domain in second-generation chimeric antigen receptors
#58Compositions comprising fusion proteins useful for modulating an immune response
#59Anti-angiogenic agent and methods of using such agent
#60XBP1, CD138, and CS1 peptides
#61Therapeutic use of anti-CS1 antibodies
#62Use of the CD2 signaling domain in second-generation chimeric antigen receptors
#63Therapeutic use of anti-CS1 antibodies
#64Anti-angiogenic agent and methods of using such agent
#65Therapeutic use of anti-CS1 antibodies
#66XBP1, CD138, and CS1 peptides
#67Polynucleotides encoding concatameric immunoadhesion molecules
#68Therapeutic use of anti-CS1 antibodies
#69Therapeutic use of anti-CS1 antibodies
#70THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
#71Diagnosis of autoimmune disease
#72Concatameric immunoadhesion molecule
#73Inhibiting rejection of a graft
#74Organic compounds
#75Method of modulating memory effector T-cells and compositions
#76Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction
#77Novel human hemicentin proteins and polynucleotides encoding the same
#78Therapeutic use of anti-CS1 antibodies